Author

Chuck Bullock

Institution: PDL BioPharma (United States)

Observed institutions: PDL BioPharma (United States), Institut of Research in Solar Energy and New Energies

OpenAlex ID: A5013372966

Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates

2004 · Paul R. Hinton, Mary G. Johlfs, et al. · Journal of Biological Chemistry · 277

A HUMANIZED ANTI-CD3 ANTIBODY, HuM291, WITH LOW MITOGENIC ACTIVITY, MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES

1999 · Di-Hwei Hsu, Jia Dong Shi, et al. · Transplantation · 45

In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells

2002 · Jia Dong Shi, Chuck Bullock, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 28

A HUMANIZED ANTI-CD3 ANTIBODY HuM291 MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES

1999 · Di-Hwei Hsu, Jia Dong Shi, et al. · Transplantation

Works count: 4

Citation count: 350

H-index: 3

I10-index: 3